Structure-Guided Designed [¹⁸F]-labeled FAPI for Enhanced Hydrophilicity: From

797.7 KB of data supporting a first-in-human study of [18F]AlF-NOTA-GL01, a fibroblast activation protein (FAP)-targeting PET imaging agent. The dataset, uploaded by Xingyu Mu in May 2026, likely contains results from preclinical xenograft models and initial human trials, including metrics like radiochemical purity (>95%), binding affinity (IC50 = 2.94 nM), and tumor uptake (7.45 ± 2.34%ID/g at 60 min).

Use Cases

• Compare tumor uptake and biodistribution of novel FAP-targeting agents based on reported preclinical PET imaging results.
• Evaluate the hydrophilicity and clearance profile of radiopharmaceuticals based on the reported LogD value and renal clearance data.
• Assess clinical translation potential of imaging agents based on first-in-human study data comparing target-to-background ratios against established tracers like FDG and FAPI-42.

Strengths

• Includes specific, quantitative metrics: radiochemical purity >95%, binding affinity IC50 = 2.94 nM, hydrophilicity LogD = -3.06.
• Contains data from both preclinical (A549-hFAP xenografts) and clinical (first-in-human) stages of development.
• Reports comparative imaging results against established tracers [18F]FDG and [18F]FAPI-42.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal/source bias inherent to a single research study on figshare.

Provenance

Source

Xingyu Mu

Freshness

Last updated 2026-05-29 09:13:28; freshness should be verified.